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Chronic Heart Failure: A "Perfect Storm" of Multiple Organ System Dysfunction
As the heart fails, following a myocardial infarction or other etiology, cardiac output (Q TOT ) at rest, and particularly during muscular exercise, is reduced consequent to a diminished ejection fraction, stroke volume, and a heart rate response that is insufficient to compensate for the reduced stroke volume. This is the initiating condition for a cascade of events that affects multiple organ systems ( Fig. 1; and Rev. 129, 130) .
There is a global sympathetically mediated vasoconstriction that initially serves to maintain Q TOT at prepathology levels and that subsequently impairs the ability to distribute and redistribute Q TOT to and within skeletal muscle(s) (Q m; 120, 124, 160, 173) . Enhanced humoral mediators including altered circulating angiotensin, norepinephrine, endothelin-1 (154) , and vasopressin levels also contribute to the systemic vasoconstriction in chronic heart failure (CHF), and intravascular sodium and water retention act to further impair vasodilation (177) , as do a plethora of events within the peripheral vasculature (vide infra; 25, 44, 45; Rev. 129, 130) . In addition, group III (mechanosensitive) and IV (metabosensitive) afferents within the contracting muscles increase global sympathoexcitation (9, 35, Rev. 164) . In support of the "muscle hypothesis" of Coats et al. (31) for CHF, Wang et al. (164) have demonstrated that CHF sensitizes group III afferents, which likely contributes to the exaggerated exercise pressor response (EPR). Despite the same studies demonstrating that group IV afferents are desensitized in CHF, it is pertinent that the far slower O 2 uptake (V O 2 ) kinetics, lower V O 2 , and microvascular PO 2 (Pmv O 2 ) (Figs. 2-6) will all exacerbate the production and accumulation of metabolites that ultimately stimulate these afferents. Thus, despite their relative desensitization, the role of the group IV afferents in the EPR is likely substantial in CHF. This eventuality would certainly help explain how exercise training-induced speeding of the V O 2 kinetics (131, 139) reduces or even prevents a greater EPR in CHF (165) .
At the proximal end of the O 2 transport pathway in the lung, patients with CHF develop pulmonary dysfunction including ventilation-perfusion (V A /Q ) mismatch accompanied by reduced O 2 diffusing capacity (5, (83) (84) (85) 170, Rev. 126) and diminished respiratory endurance (112) . Whereas the V A /Q mismatch and diffusional impairments are often so mild that they do not cause arterial hypoxemia, they are accompanied by a chronic hyperventilation resulting from sensitization of the peripheral chemoreceptors (carotid bodies; 151) that, in concert with restrictive and obstructive pulmonary abnormalities, increases the work of breathing (Rev. 126). During severe intensity exercise in health, the diaphragm and other respiratory muscles can "steal" Q from the locomotory muscles (79) . Fig. 1 . Predations of chronic heart failure (CHF) on the O2 transport pathway. Although a dysfunctional heart and impaired ability to generate cardiac output are the core events, CHF is a multiorgan disease affecting all steps in the O2 transport pathway. CHF-induced lung dysfunction redistributes blood flow (Q ) to the respiratory muscles via locomotory muscle vasoconstriction; there may be systemic anemia, systemic vasoconstriction, and elevated left ventricular (LV) end-diastolic pressures (LVEDPs) as well as a plethora of structural and functional adaptations (increased vasoconstriction, impaired vasodilation, and muscle pump) that compromise skeletal muscle perfusional and diffusional O2 transport. V A, alveolar ventilation; V E, expired ventilation; SNS, sympathetic nervous system; Q O2, whole body oxygen delivery (cardiac output ϫ arterial O2 content); V O2, oxygen uptake; NO, nitric oxide; iNOS, inducible NO synthase; ROS, reactive oxygen species; SOD, superoxide dismutase; GPX, glutathione peroxidase. See text for more details.
In CHF this effect is accentuated (122, 126) , redistributing more Q TOT toward the respiratory muscles and, by heightening sympathetic vasoconstriction of locomotory muscles, further impoverishing their Q m and O 2 supply and compromising exercise tolerance. This condition may be exacerbated further if CHF is accompanied by anemia secondary to dysfunctional iron metabolism and heightened inflammatory stress (103) . Furthermore, within skeletal muscles in CHF, the capacity to use O 2 is impaired with reductions in mitochondrial oxidative enzyme activity and volume density as well as mitochondrial dysfunction (e.g., 41, 58, 65, 78, 153) . It is pertinent that although skeletal muscle capillarity may (e.g., 171) or may not (58) be reduced significantly, across control and CHF populations, the number of capillaries per fiber correlates highly with mitochondrial volume density (58) . In addition, CHF increases the proportion of capillaries that do not support red blood cell (RBC) flux at rest and during contractions (137) .
Impact on Exercise Responses
Four key parameters of aerobic function are the maximum V O 2 (V O 2 max ), V O 2 kinetics, V O 2 gain (e.g., ml O 2 ·watt Ϫ1 ·min Ϫ1 for cycling, an approximate measure of efficiency), and the lactate threshold (Tlac) or gas exchange threshold (131, 133-135, 139, 168, 169) . These parameters define the gas exchange (i.e., V O 2 ) response to exercise in the transient (i.e., following exercise onset, non-steady state) and steady-state conditions and, as such, link tightly with exercise tolerance or impediment thereof.
Maximum V O 2 . V O 2 max has been historically considered the sentinel parameter of integrated cardiovascular function and has been widely used to judge the severity of CHF (52, 71, 98, 109, 111, 167, 168) . Specifically, class A, V O 2 max Ͼ 20 ml·kg Ϫ1 ·min Ϫ1 ; class B, 16 -20; class C, 10 -15; and class D, Ͻ10, which broadly correspond to the New York Heart Association classifications I, II, III, and IV, respectively (167) . Accordingly, it is instructive to consider the determinants of V O 2 max and what insights these can provide into the mechanisms by which CHF compromises systemic and muscle O 2 transport.
Wagner and colleagues (138, 162, 163) have championed the notion that although perfusive cardiovascular O 2 delivery may be the strongest determinant of V O 2 max in young healthy individuals exercising at sea level [evidenced by inspired hyperoxia (94) , pericardectomy (152) , blood doping (70) , and small muscle mass exercise (137) , all increasing V O 2 max or muscle specific V O 2 max ], pulmonary and muscle diffusive O 2 capacities also contribute importantly to V O 2 max . Moreover, at altitude, after exercise training, and in extremely fit individuals (high V O 2 max ), the relative importance among O 2 perfusive and diffusive capacities with respect to determining V O 2 max may shift. In CHF, it was traditionally thought that V O 2 max was reduced solely consequent to the lowered Q TOT and resultant Q m (perfusive O 2 transport), which was supported by the low venous O 2 contents measured either centrally (pulmonary artery) (167) or in the exercising muscle(s) effluent venous blood (88) . Specifically, the ability to reduce venous O 2 content and increase fractional O 2 extraction (arterial-venous O 2 difference) to a similar (or better) extent as seen in healthy subjects led to the presumption that the effective muscle O 2 diffusing capacity (DO 2 m) was unimpaired. However, as can be seen from Fig. 2 V O 2 kinetics. Healthy individuals, let alone patients with CHF, rarely exercise at V O 2 max , yet daily activities require myriad increases (and decreases) in metabolic rate and hence V O 2 . The speed of these adjustments define ones' V O 2 kinetics in terms of the overall time constant (, time to reach 63%) of the response which may be 20 -30 s in young healthy individuals but slowed to several minutes in patients with CHF ( Fig. 3 ; 81, 118, 147, 148) . Importantly, the speed of the V O 2 kinetics has been considered to have even better prognostic value in CHF than V O 2 max (on-kinetics, 142; off-kinetics, 125). Both the close-toinstantaneous phase I (driven predominantly by increased pulmonary blood flow, omitted from Fig. 3 for clarity) and the subsequent primary (phase II) response, thought to reflect the muscle V O 2 kinetics (72), are impacted by CHF (148), reflecting a failure to both increase Q TOT and muscle V O 2 . The importance of this slowed V O 2 kinetics is that the steady-state O 2 requirement for a given task will almost certainly be no lower (and may even be higher, see below) in CHF, and so, for any given metabolic transition, the patient with CHF will incur a greater O 2 deficit and therefore more extreme intracellular perturbation of high-energy phosphagens and acid-base ( Fig.   3 ). Importantly, the greater substrate-level phosphorylation associated with slower V O 2 kinetics accelerates glycogenolysis and contributes to fatigue and the ensuing exercise intolerance (123, 131, 139) . For a given metabolic transition (⌬V O 2 ), the O 2 deficit incurred may be estimated as ⌬V (Fig. 4 , Refs. 80, 86, 134, 135, 169) . This extra V O 2 arises predominantly from within the exercising muscles and is attributed to a combination of fatigue-related processes necessitating additional fiber recruitment and also metabolic processes occurring within already recruited fibers (133, 159) . In healthy individuals this slow component may exceed 1 liter O 2 /min, reduce exercise efficiency, and for severe exercise (i.e., above the critical power, the asymptote of the hyperbolic relationship between power output and time to exhaustion for high-intensity exercise), drive V O 2 to V O 2 max , heralding imminent fatigue (135, Rev. 86) . For the patient with CHF, whose Tlac (69, 89, 178) and critical power (131, 139) often reside at perilously low absolute V O 2 values, the slow component represents a metabolic extravagance that they can ill afford. Indeed, the presence of Tlac and critical power in patients with CHF at metabolic rates (V O 2 values) far lower than seen in healthy individuals means that patients in whom muscle O 2 delivery is most compromised may actually have the highest O 2 requirement for muscular exercise (including a higher O 2 cost incurred by the respiratory muscles, 126) even at very low work rates. As initially documented by Zelis and colleagues (173) , the actual V O 2 achieved by the patient with CHF during exercise may be lower than that for their healthy counterpart. Given the above, this should not be taken as evidence that the patient with CHF is working more efficiently. Indeed, the opposite may be the case and the lower achieved V O 2 means that the patient is accumulating a greater (and continuous) O 2 deficit leading to premature exhaustion. Fig. 3 . Facets of the exercise response in CHF: V O2 kinetics. CHF slows V O2 kinetics (increased time constant, ) in response to moderate (as shown), heavy, and severe intensity exercise, in part, by lowering muscle perfusive and diffusive O2 transport such that O2 delivery becomes limiting (top, see gray O2 delivery-dependent zone). Note that these slowed V O2 kinetics will mandate a greater O2 deficit leading to greater intracellular perturbations that accelerate glycogen depletion and sow the seeds for exercise intolerance. Mechanisms responsible for slowed V O2 kinetics in CHF include slowed/absent arteriolar vasodilation, impaired muscle pump (venous congestion), slowed capillary hemodynamics, lowered PmvO 2 , impaired mitochondrial function, and greater intracellular perturbation (as detailed in bottom). PCr, phosphocreatine; ADPfree, free adenosine diphosphate. See text for additional details.
To understand the mechanisms underlying the exercise intolerance of CHF, the bases for the decreased V O 2 max , slowed V O 2 kinetics, lowered Tlac and critical power, and increased V O 2 gain must be explored. As will be seen, these bases emerge strongly from compromised Q m and an inability to temporally and spatially match Q O 2 m to requirements (V O 2 ). O 2 Healthy. In healthy individuals with normal arterial O 2 content (ϳ20 ml O 2 /100 ml), Q TOT and Q m increase between 5 and 6 liters per liter V O 2 (Rev. 60). Following the onset of muscular exercise the Q TOT increase is extremely rapid owing to an essentially instant vagal withdrawal accelerating heart rate (phase I) with a subsequent increase in stroke volume and further elevation of heart rate (phase II), driving Q TOT and Q m kinetics that are appreciably faster than their V O 2 counterparts (40, 95, 133, 157, 172) . This profile supports the O 2 delivery independence of V O 2 kinetics in healthy young individuals ( Fig. 3; Refs. 133, 139 ). Thus Q m may increase sufficiently fast for moderate (72) as well as heavy and severe exercise (13, 96) , such that increased Q O 2 m exceeds muscle V O 2 and consequently effluent venous O 2 content increases transiently as fractional O 2 extraction is decreased. There is evidence that both rapid arteriolar vasodilation (19, Rev. 28) and muscle pumping action (Rev. 157) contribute to this almost instantaneous (within 1 s) increase in muscle (95, 157) and capillary (92) Q .
Skeletal Muscle Blood Flow, Capillary Hemodynamics, and Pmv
Across muscles of different fiber type composition, the proportionality of the increase in Q m to V O 2 is similar, but fast twitch muscles have a lower Q m at rest such that Pmv O 2 is lower (and fractional O 2 extraction higher) at rest and low metabolic rates than for slow twitch muscles (23, 60, 117) . These fast twitch muscles may have a slower rate of Q m increase following the onset of contractions and may be forced to rely more heavily on O 2 extraction than slow twitch muscles (23, 117) . Importantly, as most skeletal muscle capillaries may support RBC flux at rest, the increased Q m with contractions represents augmented RBC flux (and velocity) within already flowing capillaries (92, 132) . Thus, following the onset of contractions, increased blood-muscle O 2 flux (diffusional O 2 capacity, DO 2 m) occurs via a combination of the following (132): 1) increased RBC flux and velocity in individual capillaries, 2) recruitment of additional capillary exchange surface by elevating capillary hematocrit and the length of capillary over which O 2 flux occurs (i.e., "longitudinal recruitment"), 3) reduction of intramyocyte PO 2 to establish a sufficient capillary-mitochondrial O 2 gradient, and 4) myoglobin deoxygenation to enhance intramyocyte O 2 movement.
Chronic heart failure. CHF may attenuate or even abolish the initial rapid increase in Q TOT (and thus Q m; 146) following exercise onset (i.e., phase I; 148) and result in an extremely slow and often an inadequate subsequent elevation of Q m (phase II; 108, 174 -177). For a share of this reduced Q O 2 , exercising skeletal muscle must overcome exaggerated sympathetic, humoral, and reflex-mediated vasoconstriction to compete with elevated energetic (and Q m) demands of the respiratory muscles (122, 126) and an altered distribution of available Q TOT among active locomotory muscles based on, in part, their fiber-type composition (i.e., greater Q m to low oxidative type II and lower Q m to type I/oxidative type II muscles and muscle fibers in CHF vs. healthy animals; 51, 124). At V O 2 max the reduced Q TOT (and any decreased arterial [O 2 ]) lowers Q O 2 m, whereas subsequent redistribution of that lowered Q TOT away from the major locomotory muscles provides an additional constraint on Q O 2 m (122, 126, Fig. 2 ). Compounding these Q TOT distributional problems, arterioles within the active muscles themselves have an inherently greater vasoconstrictor tone (44, 45) .
At the muscle capillary level, CHF promotes capillary involution (171) and reduces the percentage of capillaries that support RBC flux at rest and during contractions (136) . Crucially, those capillaries that do not flow at rest remain stagnant during contractions, and this helps place a low limit on DO 2 m (see Fig. 2 ) as it lowers the number of oxygenated RBCs in the capillary bed at a given moment and therefore available to contribute to the instantaneous blood-myocyte O 2 flux. Figure 5 , top, demonstrates that even in those capillaries that do support RBC flux at rest, the response to contractions is extremely sluggish. Consequently, even though mitochondrial V O 2 kinetics may be impaired in CHF (and especially severe CHF, 41), Q O 2 m kinetics are more affected and the Q O 2 m-to-V O 2 ratio falls much lower driving Pmv O 2 , either transiently (moderate CHF in young animals, Fig. 5, bottom; 46) or during the steady-state (severe CHF, old animals; 21, cf. 18, 22) to extremely low values. Importantly, muscles predominantly comprised of slow Fig. 4 . Facets of the exercise response in CHF: lactate threshold (Tlac). These curves are constructed from the end-exercise V O2 obtained in a series of independent constant-work rate exercise tests performed in a healthy individual (top) and a patient with CHF (bottom). Note the far lower work rate for the Tlac in CHF and that the V O2 slow component (gray areas) becomes evident only above Tlac. One consequence of this behavior is that the patient with CHF experiences an additional O2 demand at very low work rates that may drive V O2 to V O2 max and herald imminent exhaustion. Mechanisms responsible for the lowered Tlac and presence of V O2 slow component at very low work rates include decreased bulk blood flow and O2 delivery, reduced capillarity, impaired capillary hemodynamics, lowered PmvO 2 , and mitochondrial dysfunction, particularly in slow twitch highly oxidative (type I) fibers. See text for additional details. twitch fibers are impacted most drastically (20) . Thus, when compared with healthy muscles, in CHF the Pmv O 2 (driving blood-myocyte O 2 flux) is lowered at that time when muscle V O 2 is, or should be, increasing most rapidly with the result that V O 2 kinetics become O 2 delivery (i.e., Q O 2 m) limited and very slow (Fig. 3) . This response is akin to the "overshoot" of the muscle hemoglobin ϩ myoglobin deoxygenation profile measured by near-infrared spectroscopy by Sperandio and colleagues (150) in patients with CHF. In an attempt to preserve the blood-myocyte PO 2 gradient in the face of falling Pmv O 2 , intramyocyte PO 2 is likely to decrease and exacerbate intracellular perturbations of high-energy phosphates ([PCr], [ADP free ]), glycolysis, and acid-base (8) .
Not only is this situation sowing the seeds for premature fatigue in CHF, but it presages an extremely slow recovery as seen for Pmv O 2 in Fig. 6 . The inability to increase the Q O 2 m delivery-to-V O 2 ratio earlier or faster following cessation of muscle contractions in CHF keeps Pmv O 2 low, reduces intramyocyte PO 2 , and retards V O 2 and PCr recovery kinetics (89, 90) . It is pertinent that recovery V O 2 kinetics can often be determined with greater fidelity and reproducibility than its counterpart at the beginning of exercise (89, 90) . Thus altered off-transient V O 2 kinetics, sometimes in the presence of indiscernibly different on-kinetics, may identify O 2 transport/utilization derangements in patients with CHF (147) and therefore correspond more closely with the extent of functional compromise (39, 90, 125) . This effect has also been demonstrated for the dynamics of muscle Pmv O 2 as seen in Fig. 6 , top, for severe CHF (33) . Notice that the lowered Pmv O 2 at rest and during contractions in CHF and the Pmv O 2 "undershoot" present in the response. However, the most pronounced difference in the kinetics of the Pmv O 2 response is evident in the off-transient (i.e., recovery) where the control muscle recovers to baseline well before its CHF counterpart has reached 50% recovery. It is pertinent that Copp et al. (33) demonstrated a strong correlation ( Fig. 6, bottom ; r ϭ 0.76, P Ͻ 0.01, n ϭ 16, control, moderate CHF, severe CHF) between the slowed Pmv O 2 offkinetics and elevated left ventricular end-diastolic pressure (LVEDP), albeit driven principally by the severe CHF animals. This observation is relevant because patients with CHF often complain of prolonged fatigue that resolves very slowly following exercise or rehabilitation therapy. Ameliorating these symptoms may help improve exercise rehabilitation retention and thus efficacy in the community of patients with CHF.
Tlac (expressed as the V O 2 at which blood lactate begins increasing above values at rest, used here synonymously with the gas exchange threshold) is exquisitely sensitive to arterial O 2 content, Q O 2 m, Pmv O 2 , and muscle oxidative capacity (Rev. 166). As detailed above, each of these variables is impaired in CHF, and compounded by slowed V O 2 kinetics, it is inevitable that Tlac occurs at extremely low V O 2 values in patients with CHF (69, 89, 178) . Moreover, because of the increased respiratory muscle V O 2 (126) as well as any sympathetic stimulation of metabolic rate and/or cachexia, the range of achievable sub-Tlac work rates may be disappearingly small. Hence, daily tasks or activities that are sub-Tlac for healthy individuals invoke a systemic lactic acidosis and will therefore incur an extra V O 2 cost associated with the V O 2 slow component in patients with CHF (86, 131, 133) . With their low V O 2 max (and thus modest Tlac-V O 2 max range), it is doubtful whether the slow component effect would be as large as seen in healthy/fit individuals. However, in and of itself, this would be expected to accelerate exhaustion especially if it increases the gap between muscle ATP requirements and that generated by oxidative metabolism, thereby more rapidly depleting finite nonoxidative muscle energy stores (86, 131, 135) .
Mechanisms Limiting Increases of Muscle Blood Flow in CHF
Almost every aspect of muscle blood flow (Q m) control is disturbed in CHF as seen in Fig. 7 . Vasoconstriction is enhanced by sympathetic nervous system-mediated ␣-adrenergic tone (consequent to enhanced peripheral chemoreceptor sensitivity and heightened metaboreflexes) and increased circulating catecholamines, angiotensin II, arginine vasopressin, and endothelin-1 (25, 154, Rev. 129, 130) . The efficacy of the muscle pump is impeded by elevated postcapillary resistance (115, 146, 174, 175) and increased vascular stiffness. Endothelial function is compromised by endothelial cell damage and impaired repairability, in part because of low circulating endothelial progenitor cells (CPCs; 54). Nitric oxide (NO) bioavailability is compromised, which presumably constrains sympatholysis (the ability to oppose ␣-adrenergic vasoconstriction; 155) and shear stress-mediated vasodilation. In turn, inadequate Q m and Q O 2 m will promote hypoxic vasodilation and increase vasodilatory metabolite efflux from the contracting muscle(s) (lactate, H ϩ , adenosine, inorganic phosphate, potassium). The eventual outcome (i.e., reduced Q m and particularly Pmv O 2 ) in CHF indicates that the net balance favors reduced vascular perfusion and impaired Q O 2 m.
Within muscle and other tissues, CHF increases TNF-␣ and IL-1␤ levels and the anti-inflammatory interleukin 10 (IL-10) may decrease (14, 54) irrespective of whether circulating concentrations are altered. There is also an aggravated oxidantantioxidant imbalance. All of these changes can impact NO bioavailability and, given the importance of decreased NO bioavailability in muscle and exercise dysfunction in CHF (see Role of NO in Regulating Contracting Muscle Q O 2 /V O 2 Matching), have been the subject of significant attention.
Role of NO in Regulating Contracting Muscle Q O 2 /V O 2 Matching
NO bioavailability can exert a commanding role in the matching of Q O 2 m to V O 2 in contracting rat muscle. For example, Hirai and colleagues (82) have determined in rats that NO-mediated vasodilation helps regulate the distribution of Q O 2 m among active muscle fibers based on their oxidative capacity. In CHF, the capacity for N G -nitro-L-arginine methyl ester blockade of NO synthase (NOS, nonspecific isoform blockade) to reduce Q m, particularly to more highly oxidative muscle fibers, is substantially lessened (82) . With the use of the superfused contracting spinotrapezius preparation, NOS blockade transforms the healthy rat Pmv O 2 profile into one resembling CHF (Figs. 5 and 6; and Refs. 59, 61). Moreover, in CHF muscles, the NOS blockade effect is greatly reduced and the application of sodium nitroprusside (an NO source) restores the Pmv O 2 profile from that present in moderate CHF back to that seen in the healthy animals (59). However, it must be acknowledged that elevating intracellar [NO] has the potential to decrease mitochondrial V O 2 (10, 11, 100) and hence restore the healthy Q O 2 m-to-V O 2 ratio by decreasing the denominator as well as increasing the numerator. Notwithstanding this concern, it is evident that increased NO bioavailability has the potential to enhance blood-myocyte O 2 flux in CHF by restor- ing Pmv O 2 . This potential for compromised NO bioavailability to explain Pmv O 2 (and thus functional) derangements in CHF highlights the importance of resolving the mechanisms responsible for the reduction in NO bioavailability in CHF and developing/optimizing therapeutic strategies for mitigating this effect (Fig. 7, inset, bottom right) .
Inflammatory Mediators Reduce NO Bioavailability in CHF
CHF-induced muscle vascular dysfunction and the associated decreased NO bioavailability is mediated, in part, by a combination of the reduction in endothelial cell tetrahydrobiopterin (BH 4 , an essential cofactor for NOS), superoxide dismutase (SOD), catalase, and glutathione peroxidase protein expression and activity, as well as increased NADPH oxidase protein expression and activity, each of which serves to elevate superoxide radicals (O 2 ·Ϫ ) and decrease NO (Fig. 7 , inset, bottom right; 17, 42, 82, 93, 97, 106, 110) . Inflammatory mediators TNF-␣ and IL-1␤ promote oxidative stress and have been heavily implicated in this process (1, 2, 24, 34, 53, 65, 67, 105, 156, 158) . Reducing BH 4 uncouples endothelial NOS, lowering NO production (110, 149) and generating O 2 ·Ϫ , which itself enhances NO degradation and produces the peroxynitrite reactive oxygen species (Fig. 7, inset, bottom right,  149) . Moreover, by the action of SOD, enhanced O 2 ·Ϫ will elevate hydrogen peroxide, which, although a vasodilator in its own right, in the presence of Fe 2ϩ yields the potent vasoconstrictor hydroxyl radical via the Fenton reaction. In addition, elevated cytokines (TNF-␣, IL-1␤) promote inducible NOS induction such that intracellular [NO] rises and inhibits key oxidative enzymes and mitochondrial creatine kinase (4, 65, 76) as well as promoting apoptosis (3) .
In aged rats, increased BH 4 , induced via acute exogenous bolus sepiapterin (substrate for BH 4 synthesis) treatment or exercise training, improves NO signaling in skeletal muscle arterioles and restores flow-induced vasodilation (149) . Whether this is also the case in CHF is an important question given the commonality between the conditions of aging and CHF with respect to these inflammatory mediators (i.e., TNF-␣ and IL-1␤). It is pertinent that pentoxifylline, a phosphodiesterase inhibitor that also blocks cytokine expression reducing circulating and tissue TNF-␣ and IL-1␤, improves capillary hemodynamics in ischemic conditions (in this respect analogous to CHF; 38, 50, 145) and has demonstrated clinical efficacy in patients with CHF (12, 145) . Pentoxifylline may also help restore more normal skeletal muscle hemodynamics in CHF by reducing the CHF-enhanced sympathoexcitation via central effects within the paraventricular nucleus and elsewhere (75) . However, this remains to be empirically determined.
Specific Effects of CHF and Exercise Training on Mediators of NO Bioavailability
In contrast to CHF, NO bioavailability and endothelial function in skeletal muscle and heart are upregulated by exercise training (73, 101, 114, 144) particularly against a background of CHF ( Fig. 8; 34, 161 ). The effect of exercise training and its ability to combat the predations of CHF has been attributed, in part, to increased BH 4 (16, 106) , as well as decreased oxidative stress (increased SOD, catalase, and glutathione peroxidase; 62, 68, 102, 106, 140), reduced TNF-␣ and IL-1␤ (1, 32, 66, 104) , and reduced inducible NOS that decreases intramyocyte [NO] and presumably lessens its pernicious intracellular consequences (65) . Moreover, exercise training may increase muscle capillarity [facilitated by preservation of the vascular endothelial growth factor signaling pathway in patients with CHF, 57] and oxidative function in patients with CHF (56) as it does in healthy individuals (26, 141) , as well as restore levels of the anti-inflammatory mediator IL-10 (14). In addition, exercise training may improve vascular endothelial function via a c-Src-dependent increase of endothelial NOS expression and NO bioavailability as well as help restore endothelial repair and function by elevating CPCs (37, 54, 56, 62, 97, 101, 114) . As such, strategies that enhance NO bioavailability while decreasing the predations of inflammatory cytokines (TNF-␣, IL-1␤) and possibly increasing anti-inflammatory cytokines (IL-10) and CPCs, for example, exercise training (66), pentoxifylline, statins (e.g., rosuvastatin, 54), and antioxidant strategies (but not acute vitamin C; 55), offer hope. In addition, if dietary nitrate supplementation can improve exercise efficiency (reduced V O 2 gain) in patients with CHF as it does in healthy individuals (10, 11, 99, 100) , Q O 2 m-to-V O 2 matching will be enhanced and exercise tolerance might be improved without the necessity for increased Q m, fractional O 2 extraction, or altered Q m distribution. Finally, the demonstration that vascular signaling mechanisms are retained in patients with CHF (e.g., vascular endothelial growth factor; 57) coupled with the ability for ventilatory assist devices to redistribute Q TOT to the locomotory muscles (126) and specific respiratory muscle training to enhance limb Q m and exercise tolerance in patients with CHF (27, 36, 113) suggests innovative strategies for improving cardiac rehabilitation program retention and outcomes.
Conclusions
The challenge for physiologists, exercise specialists, and clinician scientists is to resolve the specific mechanisms underlying CHF-induced dysfunction at each step in the O 2 transport pathway. This is crucial to increase exercise tolerance most effectively in the patient with CHF; in this regard, it is clear that even very aggressive contemporary pharmaceutical treatment is not reversing the Q O 2 m-to-V O 2 mismatching aberrations in skeletal muscle (150) . In turn, those improvements in exercise tolerance need to be quantified appropriately (168) and related to the parameters of aerobic function. As proposed by Coats and colleagues (31), skeletal muscle plays center stage in the dysfunction and prognosis of the patient with CHF and recent evidence is emerging for contracting skeletal muscles producing "myokines" that actively oppose the inflammatory condition of CHF (and other diseases/conditions) (127, 128) . This is exciting and particularly relevant to CHF because small initial improvements in the O 2 transport pathway, insofar as these increase V O 2 max and Tlac, and speed V O 2 kinetics, thereby improving exercise tolerance, may initiate a positive feedback that eventually reverses many of the predations of CHF. Joyner's (87) example of a young man, Chad Carvin, who recovered from heart failure to win a silver medal in Fig. 8 . Endurance exercise training opposes many of the dysfunctional elements of CHF and facilitates improved skeletal Q m, pulmonary gas exchange (V O2), and exercise tolerance. Note that the scope of these exercise training adaptations presents a substantial challenge to current and future pharmacotherapeutic approaches to treating patients with CHF (150) . References cited for each organ/system are emblematic rather than comprehensive. Note that inspiratory muscle training also increases locomotory Q m, V O2 max, and exercise tolerance (27, 36, 113) . dP/dt, first derivative of LV pressure; HRmax, maximum heart rate, RVLM, rostral ventrolateral medulla; NT-BNP, amino-terminal pro-brain natriuretic peptide. See text for more details.
swimming (4 ϫ 200 m freestyle relay) at the 2000 Olympic Games in Sydney, provides evidence that, beyond the failing heart, the O 2 transport predations of CHF are potentially reversible. 
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